Neumora Therapeutics posts corporate presentation on neuroscience drug development strategy

• Neumora outlined a pipeline spanning cardiometabolic, neurodegenerative, neuropsychiatric programs, with multiple readouts expected in 2026.
• NMRA-215 NLRP3 inhibitor: IND submission targeted for 4Q 2026; Phase 1 start planned by year-end 2026 for obesity.
• Preclinical DIO studies showed up to 19% weight loss on NMRA-215 monotherapy; up to 26% when combined with semaglutide.
• NMRA-511 V1aR antagonist: Phase 1b in Alzheimer’s agitation showed Cohen’s d 0.34 at Week 8 in NPI-AA ≥4 population.
• NMRA-898 M4 modulator: Phase 1 data expected in 2H 2026 for schizophrenia; Phase 2 for NMRA-511 planned by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.